Solid Biosciences Inc. (SLDB) financial statements (2020 and earlier)

Company profile

Business Address 141 PORTLAND STREET, FIFTH FLOOR
CAMBRIDGE, MA 02139
State of Incorp. DE
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments84122
Cash and cash equivalents7686
Short-term investments736
Other undisclosed current assets36
Total current assets:86129
Noncurrent Assets
Operating lease, right-of-use asset5
Property, plant and equipment1210
Restricted cash and investments00
Other noncurrent assets00
Total noncurrent assets:1711
TOTAL ASSETS:103140
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1612
Accounts payable74
Accrued liabilities98
Debt20
Other liabilities00
Total current liabilities:1812
Noncurrent Liabilities
Long-term debt and lease obligation51
Finance lease, liability1
Capital lease obligations1
Operating lease, liability4
Liabilities, other than long-term debt 1
Other liabilities 1
Total noncurrent liabilities:52
Total liabilities:2314
Stockholders' equity
Stockholders' equity attributable to parent80125
Common stock00
Additional paid in capital396324
Accumulated other comprehensive income (loss)0(0)
Accumulated deficit(316)(199)
Total stockholders' equity:80125
TOTAL LIABILITIES AND EQUITY:103140

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Operating expenses(119)(76)
Operating loss:(119)(76)
Nonoperating income21
Investment income, nonoperating21
Other nonoperating income10
Net loss available to common stockholders, diluted:(117)(75)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(117)(75)
Other undisclosed comprehensive income00
Comprehensive loss, net of tax, attributable to parent:(117)(75)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: